Takeda pharmaceuticals news
Takeda said it will reduce headcount by about 2,800 by the end of 2015 and consolidate R&D sites following last year's acquisition of Nycomed for €9.6 billion ($12.9 billion). The consolidation will include a potential merger or liquidation of its European subsidiaries, while the headcount reductions will comprise about 2,100 positions in Europe and 700 positions in the U.S. Takeda said the cuts, which will come from all areas of the company, represent about 9% of its global workforce.
The pharma also said it will shift from a product portfolio focused on mature, high-selling products to "a more diverse portfolio focused on new products." The pharma expects the changes to result in total cost savings of about ¥200 billion ($2.6 billion) over FY2011-15. ...